US FDA denies Genzyme's Clolar for acute myeloid leukaemia
This article was originally published in Scrip
The US FDA has declined to approve Genzyme's oncologic agent Clolar (clofarabine) for previously untreated elderly adults with acute myeloid leukaemia (AML) absent a randomised, controlled clinical trial in this population, the company said.
You may also be interested in...
US FDA received 110 designation requests in July, a high mark that reflects the 60 days needed to review such requests ahead of the 30 September statutory expiration; agency is allowing email submission of RPD and orphan drug designation requests during the COVID-19 pandemic and expects to roll out an online portal for orphan designation requests later this year.
Most vaccines will be distributed centrally by McKesson, but those with ultra-cold storage requirements will be shipped directly from the manufacturer to the vaccination site. Data exchange system will enable public and private databases to talk to each other and help ensure individuals receive timely revaccination with a second dose of the same vaccine regardless of location.
As agency observers wonder whether and how political considerations will impact the timing of a COVID-19 vaccine approval or authorization, the Pink Sheet looks at instances through the years where agency staffers found themselves operating under precedents with which they disagreed or that didn’t work out as expected.